Skip to content
MaxCyte Logo
  • Home
  • About Us
    • Leadership
    • Board of Directors
    • Company History
    • Distributors
    • Careers
    • Legal
  • Non-Viral
  • Products
    • Instruments
      • ATxâ„¢
      • GTxâ„¢
      • STxâ„¢
      • VLxâ„¢
    • Consumables
      • RUO Processing Assemblies
      • Processing Assemblies Accessories
      • GMP Processing Assemblies
      • Processing Assemblies Order / Quote Request
  • Resources
    • Applications
      • Cell-Based Assays
      • Gene Editing
      • Primary Cells
      • Protein Production
      • Stem Cells
      • TCR/CAR T
    • Publications
      • Application Notes
      • Posters
      • Primary Literature
      • Product Literature
      • Webinars
      • White Papers
      • Scientific Brief
      • Scientific Presentation
  • Investors
  • Events
    • News
      • MaxCyte® Minutes
      • Twitter feed
      • Virtual 3D booth
      • News Releases
    • Events
      • Upcoming Events
      • Webinars Series
      • Event Calendar
      • Investor Events
  • Contact Us
Previous Next
  • View Larger Image

Efficient mRNA-based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-induced ADCC against Lymphoma and Targets NK cell Migration Towards the Lymph Node Associated Chemokine CCL19

St Jones2021-10-04T17:07:10+00:00March 22nd, 2016|Comments Off on Efficient mRNA-based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-induced ADCC against Lymphoma and Targets NK cell Migration Towards the Lymph Node Associated Chemokine CCL19

Share This Story, Choose Your Platform!

FacebookTwitterLinkedInRedditWhatsAppTumblrPinterestVkEmail

MaxCyte, Inc.

9713 Key West Avenue
Suite 400
Rockville, MD 20850
Tel: +1-301-944-1700
Fax: +1-301-944-1703

Life Sciences

Consumables

Careers

Legal

Applications

Investors

ExPERT Platform

MaxCyte Minutes

Instruments

About Us

Resources

Distributors

Contact Ustwitter linkedin

© 2022 MaxCyte, Inc. All rights reserved. MaxCyte®, MaxCyte ATx®, MaxCyte GTx®, MaxCyte STx®, MaxCyte VLX®, Flow Transfection®, Flow Electroporation®, Any Cell. Any Molecule. Any Scale.®, CARMA®, ®, ®, ® and ® are trademarks of MaxCyte, Inc., registered in the U.S. Patent and Trademark Office. MaxCyte GTxTM, MaxCyte STxTM, ExPERT ATxTM, ExPERT GTxTM, ExPERT STxTM, ExPERT VLxTM, ExPERTTM, ATxTM, GTxTM, STxTM, VLxTM, TM, TM, MaxCyte CARMATM and CARMA Cell TherapiesTM are trademarks of MaxCyte, Inc.

Go to Top